Compass Pathways rises after FDA clears PTSD trial plan

Compass Pathways shares rose about 5% premarket after the FDA accepted its Investigational New Drug application for COMP360 to treat PTSD, clearing the way for a Phase 2b/3 trial. The study will test efficacy and safety over 12 weeks with a long-term extension. Compass also said it is in talks with the FDA about a rolling NDA for treatment-resistant depression.